AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15496223 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-OH risperidone
Number of subjects: 16
Study 15496223 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (Donepezil + Risperidone and Donepezil only)
Number of subjects: 16
Study 11468204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 10
Study 9736892 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention (twice‐weekly for 18 weeks)
Number of subjects: 24
Study 9736892 — intervention group
Group type: COMPARATOR
Intervention: Control goals (randomly selected)
Number of subjects: 24
Study 7991113 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisaccade task in advanced parkinsonian patients
Number of subjects: 32
Study 7991113 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergics
Number of subjects: 32
Study 3276492 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg, intravenous injections, three times weekly)
Number of subjects: 119
Study 3276492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 3276492 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 119
Study 30921049 — intervention group
Group type: EXPERIMENTAL
Intervention: J-Pouch (JP)
Number of subjects: 167
Study 30921049 — intervention group
Group type: COMPARATOR
Intervention: Side-to-end Anastomosis (SE)
Number of subjects: 167
Study 28675927 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold nanoparticles (NPs)
Number of subjects: 269
Study 26166526 — intervention group
Group type: EXPERIMENTAL
Intervention: Filling intervention group (received filling of the permanent teeth free of charge for 3 years)
Number of subjects: 691
Study 26166526 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education group (received oral health education for 3 years)
Number of subjects: 691
Study 26166526 — intervention group
Group type: COMPARATOR
Intervention: Control group (only accepted oral examination for 3 years)
Number of subjects: 691
Study 23322676 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (4 years)
Number of subjects: 20340
Study 23322676 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid (3 years)
Number of subjects: 20340
Study 23322676 — intervention group
Group type: COMPARATOR
Intervention: Denosumab (3 years)
Number of subjects: 20340
Study 23322676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20340
Study 22069382 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency left temporal rTMS
Number of subjects: 56
Study 22069382 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low-frequency right prefrontal followed by low-frequency left temporal rTMS
Number of subjects: 56
Study 19863301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried blood spots stored for 1, 5, 10, 15, or 20 years
Number of subjects: 5
Study 17223245 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA paddles technique
Number of subjects: 0
Study 17223245 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA hands free technique
Number of subjects: 0
Study 17223245 — intervention group
Group type: COMPARATOR
Intervention: ERC paddles technique
Number of subjects: 0
Study 17223245 — intervention group
Group type: COMPARATOR
Intervention: ERC hands free technique
Number of subjects: 0
Study 15498362 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of BMSCs
Number of subjects: 69
Study 15498362 — intervention group
Group type: COMPARATOR
Intervention: Control (saline injection)
Number of subjects: 69
Study 11571242 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIG)
Number of subjects: 39
Study 11571242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9598455 — intervention group
Group type: EXPERIMENTAL
Intervention: WR 238605 (doses ranging from 4 to 600 mg)
Number of subjects: 48
Study 9598455 — intervention group
Group type: EXPERIMENTAL
Intervention: WR 238605
Number of subjects: 48
Study 8184873 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous injection of 25 mg of conjugated oestrogen
Number of subjects: 18
Study 8184873 — intervention group
Group type: COMPARATOR
Intervention: Diluent (control)
Number of subjects: 18
Study 3280829 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 or 50 mg daily)
Number of subjects: 0
Study 3280829 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (650 or 1300 mg daily)
Number of subjects: 0
Study 3280829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31722725 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 0
Study 31722725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29024892 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Review Therapy (4-week duration)
Number of subjects: 50
Study 29024892 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 50
Study 26671952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative catheter irrigation only
Number of subjects: 48
Study 26671952 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative catheter irrigation with postoperative intermittent catheter irrigation three times a day for 3 days
Number of subjects: 48
Study 24201679 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly supervised pelvic floor muscle training class and daily home exercise for 16 weeks.
Number of subjects: 175
Study 24201679 — intervention group
Group type: COMPARATOR
Intervention: No further intervention (control group).
Number of subjects: 175
Study 24201679 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk analysis of UI.
Number of subjects: 175
Study 24201679 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk analysis for women with major levator ani muscle defects.
Number of subjects: 175
Study 24201679 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk analysis for women without major levator ani muscle defects.
Number of subjects: 175
Study 21519580 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (Laskin triangular flap)
Number of subjects: 45
Study 21519580 — intervention group
Group type: COMPARATOR
Intervention: Group A (envelope flap modified by Thibauld and Parant)
Number of subjects: 45
Study 21519580 — intervention group
Group type: COMPARATOR
Intervention: Group C (envelope flap modified by Laskin)
Number of subjects: 45
Study 17360162 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 19
Study 17360162 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol
Number of subjects: 19
Study 17360162 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 15798297 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held computerized soft tissue stiffness meter (STSM)
Number of subjects: 28
Study 11773839 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute daily treatments with eardrops for 2 weeks before surgery (Group A)
Number of subjects: 101
Study 11773839 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute daily treatments for 2 weeks before surgery (Group B)
Number of subjects: 101
Study 11773839 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group C)
Number of subjects: 101
Study 11773839 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative positive bacteriology in surgical failures
Number of subjects: 101
Study 9583576 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (9%)
Number of subjects: 10
Study 9583576 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline (0.9%)
Number of subjects: 10
Study 9583576 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.9%) and Hypertonic saline (9%)
Number of subjects: 10
Study 7649712 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (GAGPS) injections (50 mg, one injection a week for five weeks)
Number of subjects: 60
Study 7649712 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (GAGPS) injections
Number of subjects: 60
Study 7649712 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 60
Study 2745867 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided pharmacokinetic method of aminoglycoside dose prediction
Number of subjects: 100
Study 2745867 — intervention group
Group type: COMPARATOR
Intervention: Nomogram approach based on creatinine clearance
Number of subjects: 100
Study 1117912 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula B (12 to 12 mg per liter iron, 32% linoleic acid)
Number of subjects: 35
Study 1117912 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulas A and B (32% linoleic acid)
Number of subjects: 35
Study 1117912 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulas A and B
Number of subjects: 35
Study 1117912 — intervention group
Group type: COMPARATOR
Intervention: Formulas C and D (lower amounts of unsaturated fatty acids)
Number of subjects: 35
Study 29554961 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbagut
Number of subjects: 50
Study 27107097 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole-based regimen (20 mg)
Number of subjects: 374
Study 27107097 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole-based regimen (20 mg)
Number of subjects: 374
Study 24884648 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions of an incompatible position task
Number of subjects: 0
Study 24884648 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate practice of the incompatible task
Number of subjects: 0
Study 24884648 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions of a compatible spatial stimulus-response task
Number of subjects: 0
Study 22959833 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniotomy (artificial rupture of membranes, ≤4 cm)
Number of subjects: 0
Study 22959833 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 20667858 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyskinesia (group III)
Number of subjects: 259
Study 20667858 — intervention group
Group type: COMPARATOR
Intervention: No dyskinesia (group I and II)
Number of subjects: 259
Study 18478470 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure for prolapse and hemorrhoids (PPH)
Number of subjects: 100
Study 18478470 — intervention group
Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy (MMH)
Number of subjects: 100
Study 16096172 — intervention group
Group type: EXPERIMENTAL
Intervention: Femal (herbal remedy made from pollen extracts)
Number of subjects: 64
Study 14633079 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (1 mg, twice-a-day) for 12 weeks
Number of subjects: 42
Study 10963819 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily dosing of glibenclamide
Number of subjects: 30
Study 10963819 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily dosing of glibenclamide
Number of subjects: 30
Study 8993084 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine or bupropion
Number of subjects: 11
Study 8993084 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 11
Study 8993084 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders (compared to healthy controls)
Number of subjects: 11
Study 8993084 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls for nonresponders)
Number of subjects: 11
Study 1456222 — intervention group
Group type: EXPERIMENTAL
Intervention: Superelastic arch wire
Number of subjects: 43
Study 1456222 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistranded steel arch wire
Number of subjects: 43
Study 1456222 — intervention group
Group type: COMPARATOR
Intervention: Postextraction control phase
Number of subjects: 43
Study 1456222 — intervention group
Group type: EXPERIMENTAL
Intervention: Second arch wire (randomly allocated)
Number of subjects: 43
Study 6703273 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine (60 micrograms in 10 ml of normal saline)
Number of subjects: 0
Study 6703273 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine (0.15 mg/kg)
Number of subjects: 0
Study 30088695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation self-efficacy at baseline and at weeks 1, 3, 5, and 10 post-target quit date
Number of subjects: 737
Study 30088695 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent smoking status verified using expired carbon monoxide
Number of subjects: 737
Study 30088695 — intervention group
Group type: EXPERIMENTAL
Intervention: Week 10 abstinence
Number of subjects: 737
Study 29400623 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 11
Study 29400623 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (CONT)
Number of subjects: 11
Study 26677830 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training alone (GS)
Number of subjects: 168
Study 26677830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and aerobic training in the same session (GCOM1)
Number of subjects: 168
Study 26677830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and aerobic training in 2 different sessions (GCOM2)
Number of subjects: 168
Study 26677830 — intervention group
Group type: COMPARATOR
Intervention: Control group (GC)
Number of subjects: 168
Study 24714059 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month physical exercise intervention
Number of subjects: 371
Study 24714059 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 371
Study 24714059 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month physical exercise intervention in subgroup with poor/moderate WAI
Number of subjects: 371
Study 23063221 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonactivated single‐irrigation protocol (NAI) using 1% NaOCl
Number of subjects: 50
Study 23063221 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic multi‐irrigation protocol (PUI) using 1% NaOCl, 17% EDTA, and 2% chlorhexidine
Number of subjects: 50
Study 23063221 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined NAI and PUI after CaOH(2) medication
Number of subjects: 50
Study 23063221 — intervention group
Group type: EXPERIMENTAL
Intervention: Second‐visit instrumentation
Number of subjects: 50
Study 20067433 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 459
Study 20067433 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (40 mg)
Number of subjects: 459
Study 17340064 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d)
Number of subjects: 30
Study 17340064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16125367 — intervention group
Group type: EXPERIMENTAL
Intervention: TAR (Training Affect Recognition) - a computer-aided 12-session program focusing on facial affect recognition
Number of subjects: 77
Study 16125367 — intervention group
Group type: COMPARATOR
Intervention: CRT (Cognitive Remediation Training) - aims to improve attention, memory, and executive functioning
Number of subjects: 77
Study 16125367 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual) - standard treatment without special training
Number of subjects: 77
Study 11870530 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation: 46.2 Gy per 12 days, 1.4 Gy per fraction, three fractions per day with 6 h interfraction interval, treating 6 days per week
Number of subjects: 70
Study 11870530 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation: 60 Gy per 6 weeks, 2 Gy per fraction, treating 5 days per week
Number of subjects: 70
Study 11870530 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation
Number of subjects: 70
Study 11870530 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 70
Study 10741095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS)
Number of subjects: 33
Study 10741095 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 33
Study 10741095 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate plus salmeterol (BDP + S)
Number of subjects: 33
Study 7857100 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT with leucovorin tablet (400 mg/day of UFT with 20 mg/day of leucovorin)
Number of subjects: 34
Study 7857100 — intervention group
Group type: COMPARATOR
Intervention: UFT alone (400 mg/day of UFT)
Number of subjects: 34
Study 1678445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (25‐30 mg/kg body weight three times daily for 5 days) plus supportive care
Number of subjects: 889
Study 1678445 — intervention group
Group type: COMPARATOR
Intervention: Supportive care only
Number of subjects: 889
Study 6354606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 20
Study 6354606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31077610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) + Parent Psychoeducation (TEPSI)
Number of subjects: 121
Study 31077610 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 121
Study 29423579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral rectus sheath block (US-BRSB) with 30 ml of 0.25% ropivacaine
Number of subjects: 60
Study 29423579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sham block)
Number of subjects: 60
Study 26875198 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg tablets (test formulation)
Number of subjects: 42
Study 26875198 — intervention group
Group type: COMPARATOR
Intervention: Gleevec 400 mg tablets (control)
Number of subjects: 42
Study 23731741 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 20
Study 23731741 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 20
Study 23731741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21710180 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI 36 hours after hCG (Group I)
Number of subjects: 204
Study 21710180 — intervention group
Group type: COMPARATOR
Intervention: IUI 24 hours after hCG (Group II)
Number of subjects: 204
Study 19451553 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education group program (8-hour program delivered in 4 sessions over 4 weeks by a trained nurse educator)
Number of subjects: 104
Study 19451553 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education group program
Number of subjects: 104
Study 19451553 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study 16815141 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 500 mcg, twice daily for 2 weeks
Number of subjects: 13
Study 16815141 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate
Number of subjects: 13
Study 12766743 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Number of subjects: 446
Study 12766743 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 446
Study 10969673 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 85
Study 10969673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 9212476 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming group (n = 20) received mivacurium 0.025 mg/kg followed by 0.225 mg/kg 3 min later
Number of subjects: 40
Study 9212476 — intervention group
Group type: COMPARATOR
Intervention: Non-priming group (n = 20) received mivacurium 0.25 mg/kg
Number of subjects: 40
Study 9212476 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 8402628 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorozole racemate 1 mg
Number of subjects: 12
Study 8402628 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorozole racemate 2.5 mg
Number of subjects: 12
Study 8402628 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorozole racemate 5 mg
Number of subjects: 12
Study 8402628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3745460 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability Scale employing Bayesian concepts and base rates
Number of subjects: 60
Study 29554399 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel
Number of subjects: 100
Study 29554399 — intervention group
Group type: COMPARATOR
Intervention: Glove finger
Number of subjects: 100
Study 25869759 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C with hepatic steatosis + NAFLD (Group 2)
Number of subjects: 405
Study 25869759 — intervention group
Group type: COMPARATOR
Intervention: IBD + dyspepsia + hepatitis C without hepatic steatosis (Group 1)
Number of subjects: 405
Study 24839862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose drink (100 g in 250 ml)
Number of subjects: 43
Study 24839862 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink (50 g in 250 ml)
Number of subjects: 43
Study 24839862 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial sweeteners in 250 ml)
Number of subjects: 43
Study 22898118 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + Exercise (Exercise)
Number of subjects: 330
Study 22898118 — intervention group
Group type: COMPARATOR
Intervention: CBT + Contact Control (Control)
Number of subjects: 330
Study 22898118 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise participation
Number of subjects: 330
Study 19500864 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi Slice Computed Tomography (MSCT) in patients with reduced LVEF
Number of subjects: 40
Study 19500864 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi Slice Computed Tomography (MSCT) in patients with clinical signs of heart failure
Number of subjects: 40
Study 19500864 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi Slice Computed Tomography (MSCT) in relation to clinical signs of heart failure and reduced LVEF
Number of subjects: 40
Study 18665934 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy plus yogurt (yogurt group, n = 168)
Number of subjects: 347